Guardant Health Net Worth
Guardant Health Net Worth Breakdown | GH |
Guardant Health Net Worth Analysis
Guardant Health's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Guardant Health's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Guardant Health's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Guardant Health's net worth analysis. One common approach is to calculate Guardant Health's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Guardant Health's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Guardant Health's net worth. This approach calculates the present value of Guardant Health's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Guardant Health's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Guardant Health's net worth. This involves comparing Guardant Health's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Guardant Health's net worth relative to its peers.
To determine if Guardant Health is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Guardant Health's net worth research are outlined below:
| Guardant Health is way too risky over 90 days horizon | |
| Guardant Health appears to be risky and price may revert if volatility continues | |
| The company generated the yearly revenue of 739.02 M. Annual Net Loss to common stockholders was (436.37 M) with gross profit of 449.22 M. | |
| Guardant Health reports about 853.69 M in cash with (239.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.35. | |
| Guardant Health has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 3500 shares by Kumud Kalia of Guardant Health at 43.1601 subject to Rule 16b-3 |
Guardant Health Quarterly Good Will |
|
Guardant Health uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Guardant Health. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Guardant Health's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Guardant Health Target Price Consensus
Guardant target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Guardant Health's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 22 | Strong Buy |
Most Guardant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Guardant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Guardant Health, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGuardant Health Target Price Projection
Guardant Health's current and average target prices are 46.24 and 44.10, respectively. The current price of Guardant Health is the price at which Guardant Health is currently trading. On the other hand, Guardant Health's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Guardant Health Market Quote on 20th of March 2025
Target Price
Analyst Consensus On Guardant Health Target Price
Know Guardant Health's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Guardant Health is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Guardant Health backward and forwards among themselves. Guardant Health's institutional investor refers to the entity that pools money to purchase Guardant Health's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 2.6 M | Two Sigma Advisers, Llc | 2024-12-31 | 2.3 M | Fuller & Thaler Asset Management Inc | 2024-12-31 | 2 M | Fidelity International Ltd | 2024-12-31 | 1.9 M | Two Sigma Investments Llc | 2024-12-31 | 1.9 M | Ubs Group Ag | 2024-12-31 | 1.8 M | Temasek Holdings Ltd. | 2024-12-31 | 1.6 M | Goldman Sachs Group Inc | 2024-12-31 | 1.5 M | Citadel Advisors Llc | 2024-12-31 | 1.5 M | Vanguard Group Inc | 2024-12-31 | 12.1 M | Blackrock Inc | 2024-12-31 | 11.7 M |
Follow Guardant Health's market capitalization trends
The company currently falls under 'Mid-Cap' category with a market capitalization of 5.41 B.Market Cap |
|
Project Guardant Health's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | 3.12 | 3.28 |
When accessing Guardant Health's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Guardant Health's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Guardant Health's profitability and make more informed investment decisions.
Evaluate Guardant Health's management efficiency
Guardant Health has Return on Asset (ROA) of (0.1695) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1695. This is way below average. Likewise, it shows a return on total equity (ROE) of (45.8447) %, which implies that it produced no returns to current stockholders. Guardant Health's management efficiency ratios could be used to measure how well Guardant Health manages its routine affairs as well as how well it operates its assets and liabilities. The Guardant Health's current Return On Equity is estimated to increase to 3.28, while Return On Tangible Assets are projected to decrease to (0.31). As of now, Guardant Health's Intangibles To Total Assets are decreasing as compared to previous years. The Guardant Health's current Debt To Assets is estimated to increase to 0.94, while Total Assets are projected to decrease to under 1.4 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.14) | (1.08) | |
| Tangible Book Value Per Share | (1.22) | (1.16) | |
| Enterprise Value Over EBITDA | (11.69) | (12.27) | |
| Price Book Value Ratio | (26.85) | (25.51) | |
| Enterprise Value Multiple | (11.69) | (12.27) | |
| Price Fair Value | (26.85) | (25.51) |
Examining the leadership quality of Guardant Health offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 7.9946 | Revenue | Quarterly Revenue Growth 0.302 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Guardant Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Guardant Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Guardant Health insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Guardant Health Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 24th of February 2025 Other Reports | ViewVerify | |
8K | 20th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of February 2025 Other Reports | ViewVerify |
Guardant Health Earnings Estimation Breakdown
The calculation of Guardant Health's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Guardant Health is estimated to be -0.85 with the future projection ranging from a low of -0.9503 to a high of -0.35. Please be aware that this consensus of annual earnings estimates for Guardant Health is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.95 Lowest | Expected EPS | -0.35 Highest |
Guardant Health Earnings Projection Consensus
Suppose the current estimates of Guardant Health's value are higher than the current market price of the Guardant Health stock. In this case, investors may conclude that Guardant Health is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Guardant Health's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 22 | 85.43% | -0.62 | -0.85 | -3.56 |
Guardant Health Earnings per Share Projection vs Actual
Actual Earning per Share of Guardant Health refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Guardant Health predict the company's earnings will be in the future. The higher the earnings per share of Guardant Health, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Guardant Health Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Guardant Health, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Guardant Health should always be considered in relation to other companies to make a more educated investment decision.Guardant Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Guardant Health's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-20 | 2024-12-31 | -0.5038 | -0.62 | -0.1162 | 23 | ||
2024-11-06 | 2024-09-30 | -0.74 | -0.88 | -0.14 | 18 | ||
2024-08-07 | 2024-06-30 | -0.74 | -0.84 | -0.1 | 13 | ||
2024-05-09 | 2024-03-31 | -0.85 | -0.94 | -0.09 | 10 | ||
2024-02-22 | 2023-12-31 | -0.86 | -0.85 | 0.01 | 1 | ||
2023-11-06 | 2023-09-30 | -0.95 | -0.73 | 0.22 | 23 | ||
2023-08-03 | 2023-06-30 | -1.18 | -0.67 | 0.51 | 43 | ||
2023-05-09 | 2023-03-31 | -1.32 | -1.3 | 0.02 | 1 | ||
2023-02-23 | 2022-12-31 | -1.37 | -1.36 | 0.01 | 0 | ||
2022-11-03 | 2022-09-30 | -1.26 | -1.41 | -0.15 | 11 | ||
2022-08-04 | 2022-06-30 | -1.21 | -1.27 | -0.06 | 4 | ||
2022-05-05 | 2022-03-31 | -1.21 | -1.21 | 0.0 | 0 | ||
2022-02-23 | 2021-12-31 | -1.15 | -0.89 | 0.26 | 22 | ||
2021-11-04 | 2021-09-30 | -0.97 | -1.06 | -0.09 | 9 | ||
2021-08-05 | 2021-06-30 | -0.85 | -0.96 | -0.11 | 12 | ||
2021-05-06 | 2021-03-31 | -0.89 | -1.09 | -0.2 | 22 | ||
2021-02-24 | 2020-12-31 | -0.57 | -0.94 | -0.37 | 64 | ||
2020-11-05 | 2020-09-30 | -0.39 | -0.78 | -0.39 | 100 | ||
2020-08-06 | 2020-06-30 | -0.38 | -0.57 | -0.19 | 50 | ||
2020-05-07 | 2020-03-31 | -0.39 | -0.29 | 0.1 | 25 | ||
2020-02-24 | 2019-12-31 | -0.31 | -0.27 | 0.04 | 12 | ||
2019-11-07 | 2019-09-30 | -0.37 | -0.14 | 0.23 | 62 | ||
2019-08-06 | 2019-06-30 | -0.36 | -0.13 | 0.23 | 63 | ||
2019-05-09 | 2019-03-31 | -0.37 | -0.3 | 0.07 | 18 | ||
2019-03-12 | 2018-12-31 | -0.35 | -0.3 | 0.05 | 14 | ||
2018-11-19 | 2018-09-30 | -0.29 | -1.94 | -1.65 | 568 | ||
2018-08-29 | 2018-06-30 | 0 | -0.28 | -0.28 | 0 |
Guardant Health Corporate Management
| Jennifer Higgins | Senior Affairs | Profile | |
| Stephen Murphy | Senior Marketing | Profile | |
| John Saia | Chief Secretary | Profile | |
| Christopher Freeman | Chief Officer | Profile | |
| John JD | Chief Secretary | Profile | |
| Zarak Khurshid | Vice Relations | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.56) | Revenue Per Share | Quarterly Revenue Growth 0.302 | Return On Assets | Return On Equity |
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.